Anyone who has been through cancer will tell you that everything about it is just horrifying. Scientists have been looking for therapies which will help treat the disease without causing so much suffering to the patients without success. Th has been the biggest dream for Clay Siegall, the co-founder and current president of Seattle Genetics.
Seattle Genetics is a clinical trials company which is based in Seattle, Washington. Clay Siegall and his partner founded the company in 1998 with the dream of creating functional cures and mitigation measures for people with cancer. Two decades after they started, the company has had drugs approved by the FDA, and they have been listed on NASDAQ.
Clay says that his inspiration to work in clinical trials came from an ordeal he saw a close relative of his go through. The pain of watching helplessly as the person battled cancer gave him the resolve to one day change the situation if he could. He got his Bachelor of Science in zoology from the University of Maryland. He then proceeded to do masters and a Ph.D. in Genetics from the George Washington University. One of the drugs that were approved by the FDA in 2011 as an antibody-based cancer therapy is Adcetris.
He had worked in several other research companies before he left to start Seattle Genetics. Clay has been a prolific writer of science journals and is published in more than 70 of them. Besides this, he holds more than 15 patents. He says that getting to the level of success he is at right now is not simple. He revealed that there was a time when they did not even have enough funds to pay their workers’ salaries, but they still believed in their dream.
The drug is now on sale in more than 60 countries all over the world. He states that the next step for his company is getting the other 11 drugs they have been developing approval by the FDA. The company has been hiring more staff to make this dream a reality. Seattle Genetics’ success has been a result of Clay Siegall’s hard work and unrelenting spirit.